Movano Inc. reported financial results for the three months ending September 30, 2021 and provided a business update.

Movano Inc. today announced that it will be participating in Bernstein's CGM Disruptors Conference on Friday, November 19, 2021

Movano Inc. (NASDAQ:MOVE) will report third quarter 2021 financial and operating results on Thursday, November 11, 2021 at 2:00 p.m. PDT (5:00 p.m. EDT).

Movano Inc. (NASDAQ:MOVE) reported financial results for 2Q 2021 and provided a business update on highlights from the quarter.

Movano Inc. (NASDAQ:MOVE) will report second quarter 2021 financial and operating results on Thursday, August 12, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 2:00 p.m. PDT.

Movano Inc. (NASDAQ:MOVE) used its non-invasive, iPhone-sized prototype device to collect pulse pressure waveform data from 45 external participants in an IRB-approved study in the Movano Clinical Lab.

Movano Inc. (NASDAQ:MOVE) is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28.

Movano Inc. (NASDAQ:MOVE) reported financial results for the three months ending March 31, 2021 and provided a business update.

Movano Inc. (NASDAQ:MOVE) today announced that it will report first quarter 2021 financial and operating results on Thursday, May 13, 2021.

Movano Inc. (NASDAQ:MOVE), announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021.

Movano Inc. (NASDAQ:MOVE), has closed its previously announced initial public offering of 8,500,000 shares of its common stock at a public offering price of $5.00 per share.

Movano Inc. (NASDAQ:MOVE) announced the pricing of its initial public offering of 8,500,000 shares of its common stock at a public offering price of $5.00 per share.

Manufactured on GF’s 22FDX platform, Movano’s radio frequency-enabled solution will help individuals to manage their glucose levels anywhere, anytime

After announcing $10M in bridge funding in July, the company raised an additional $2.5M to progress the development of its wearable non-invasive continuous glucose monitor

Company’s needle-free wearable technology will provide painless, real-time glucose readings at the glance of a wrist